Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium

Acta Physiologica

Volumn 219, Issue 1, 2017, Pages 138-151

  Triggle, C R ^a   Ding, H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

AMPK; cancer; diabetes; EDV; metformin; SIRT1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MICRORNA; PROTECTIVE AGENT; SIRTUIN 1; ANTIDIABETIC AGENT;

ANGIOGENESIS; DRUG MECHANISM; HUMAN; META ANALYSIS (TOPIC); NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); VASCULAR DISEASE; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECTS;

ANIMALS; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; METFORMIN; PROTECTIVE AGENTS;

EID: 84954287264     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12644     Document Type: Review

References (126)

1. Allen, G.E., Montgomery, D.A.D. & Weaver, J.A. 1960. Dimethyl biguanidine dans le traitement du diabete sucre. Rev Francaise d'Endocrinol Clin 2, 1.
2. Arunachalam, G., Yao, H., Sundar, I.K., Caito, S. & Rahman, I. 2010. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun 393, 66–72.
3. Arunachalam, G., Samuel, S.M., Marei, I., Ding, H. & Triggle, C.R. 2014a. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 171, 523–535.
4. Arunachalam, G., Samuel, S.M., Marei, I., Ding, H. & Triggle, C.R. 2014b. Micro RNA-34a mediates impaired angiogenesis in diabetes: Role of SIRT1 and metformin. FASEB J 28, 1051.2 (abstract).
5. Arunachalam, G., Upadhyay, R., Ding, H. & Triggle, C.R. 2015a. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol 65, 419–429.
6. Arunachalam, G., Lakshmanan, A.P., Samuel, S.M., Triggle, C.R. & Ding, H. 2015b. Molecular interplay between microRNA-34a and sirtuin1 in hyperglycaemia-mediated impaired angiogenesis in endothelial cells: Effects of metformin. J Pharmacol Exp Ther. [Epub ahead of print]
7. Badrick, E. & Renehan, A.G. 2014. Diabetes and cancer: 5 years into the recent controversy. Eur J Cancer 50, 2119–2125.
8. Bailey, C.J. & Day, C. 2004. Metformin: its botanical background. Pract Diabetes Int 21, 115–117.
9. Bailey, C.J. & Turner, R.C. 1996. Metformin. N Engl J Med 334, 574–579.
10. Ben Sahra, I., Tanti, J.F. & Bost, F. 2010. The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 6, 670–671.
11. Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.F., Giorgetti-Peraldi, S. & Bost, F. 2011. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71, 4366–4372.
12. Berkowitz, S.A., Krumme, A.A., Avorn, J., Brennan, T., Matlin, O.S., Spettell, C.M., Pezalla, E.J., Brill, G., Shrank, W.H. & Choudhry, N.K. 2014. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med 174, 1955–1962.
13. Bhalla, R.C. & Sharma, R.V. 1996. Vascular effects of metformin. Am J Hypertens 9, 570–576.
14. Blandino, G., Valerio, M., Cioce, M., Mori, F., Casadei, L., Pulito, C., Sacconi, A., Biagioni, F., Cortese, G., Galanti, S., Manetti, C., Citro, G., Muti, P. & Strano, S. 2012. Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun 29, 865.
15. Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A.J., Kuick, R., Love, R.E., Zhai, Y., Giordano, T.J., Qin, Z.S., Moore, B.B., MacDougald, O.A., Cho, K.R. & Fearon, E.R. 2007. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17, 1298–1307.
16. Bordone, L. & Guarente, L. 2005. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 6, 298–305.
17. Brownlee, M. 2001. Biochemisty and molecular cell biology of diabetic complications. Nature 414, 813–820.
18. Caporali, A., Meloni, M., Vollenkle, C., Bonci, D., Sala-Newby, G.B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A.H., Agami, R., leSage, C., Condorelli, G., Madeddu, P., Martelli, F. & Emanueli, C. et al. 2011. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123, 282–291.
19. Chang, K.T. & Min, K.T. 2002. Regulation of lifespan by histone deacetylase. Ageing Res Rev 1, 313–326.
20. Cheang, W.S., Tian, X.Y., Wong, W.T., Lau, C.W., Lee, S.S., Chen, Z.Y., Yao, X., Wang, N. & Huang, Y. 2014. Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 34, 830–836.
21. Chen, Z.P., Mitchelhill, K.I., Michell, B.J., Stapleton, D., Rodriguez-Crespo, I., Witters, L.A., Power, D.A., Ortiz de Montellano, P.R. & Kemp, B.E. 1999. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443, 285–289.
22. Chen, Z., Peng, I.C., Sun, W., Su, M.I., Hsu, P.H., Fu, Y., Zhu, Y., DeFea, K., Pan, S., Tsai, M.D. & Shyy, J.Y. 2009. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104, 496–505.
23. Chen, Z., Peng, I.C., Cui, X., Li, Y.S., Chien, S. & Shyy, J.Y. 2010. Shear stress, SIRT1, and vascular homeostasis. Proc NatL Acad Sci USA 107, 10268–10273.
24. Davis, B.J., Xie, Z., Viollet, B. & Zou, M.H. 2006. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55, 496–505.
25. Deichmann, W.B., Henschler, D., Holmsted, B. & Keil, G. 1986. What is there that is not poison? A study of the Third Defense by Paracelsus. Arch Toxicol 58, 207–213.
26. Detaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N. & Leverve, X. 2005. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 54, 2179–2187.
27. Diabetes Control and Complications Trial Research Group 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329, 977–998.
28. Ding, H. & Triggle, C.R. 2010. Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Arch 459, 977–994.
29. Dobrina, A. & Rossi, F. 1983. Metabolic properties of freshly isolated bovine endothelial cells. Biochim Biophys Acta 762, 295–301.
30. Dolinsky, V.W. & Dyck, J.R. 2011. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 1812, 1477–1489.
31. Dumortier, O., Hinault, C. & Van Obberghen, E. 2013. MicroRNAs and metabolism crosstalk in energy homeostasis. Cell Metab 18, 312–324.
32. El-Mir, M.Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M. & Leverve, X. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275, 223–228.
33. Enkhjargal, B., Godo, S., Sawada, A., Suvd, N., Saito, H., Noda, K., Satoh, K. & Shimokawa, H. 2014. Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice. Arterioscler Thromb Vasc Biol 34, 1505–1513.
34. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. & Morris, A.D. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 21, 1304–1305.
35. Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C., Fuerth, B.J., Viollet, B., Mamer, O.A., Avizonis, D., DeBerardinis, R.J., Siegel, P.M. & Jones, R.G. 2013. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17, 113–124.
36. Faure, P., Rossini, E., Wiernsperger, N., Richard, M.J., Favier, A. & Halimi, S. 1999. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 48, 353–357.
37. Fisslthaler, B. & Fleming, I. 2009. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 105, 114–127.
38. Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F. & Viollet, B. 2010. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120, 2355–2369.
39. Fortez, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. 2014. Metformin: from mechanism of action to therapies. Cell Metab 20, 953–966.
40. Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F., Pellegrini, F. & Nicolucci, A. 2013. Metformin therapy and risk of cancer in patients with type 2 diabetes: systemic review. PLoS ONE 8, e71583.
41. Ghosh, S., Lakshmanan, A.P., Hwang, M.J., Kubba, H., Mushannen, A., Triggle, C.R. & Ding, H. 2015. Metformin improves endothelial function in aortic tissue and microvascular endothelial cells subjected to diabetic hyperglycaemic conditions. Biochem Pharmacol 98, 412–421.
42. Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J.K., Furlong, T.J., Greenfield, J.R., Greenup, L.C., Kirkpatrick, C.M., Ray, J.E., Timmins, P. & Williams, K.M. 2011. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50, 81–98.
43. Grundy, S.M., Howard, B., Smith, S. Jr, Eckel, R., Redberg, R. & Bonow, R.O. 2003. Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105, 2231–2239.
44. Hadden, D.R. 2005. Goat's rue – French lilac – Italian fitch –Spanish sainfoin: gallega officinalis and metformin: The Edinburgh connection. J R Coll Physicians Edinb 35, 258–260.
45. Hemmingsen, B., Christensen, L.L., Wetterslev, J., Vaag, A., Gluud, C., Lund, S.S. & Almdal, T. 2012. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 344, e1771.
46. Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., Spiegelman, B. & Montminy, M. 2001. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183.
47. Hou, X., Song, J., Li, X.N., Zhang, L., Wang, X., Chen, L. & Shen, Y.H. 2010. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 396, 199–205.
48. Ibáñez, L., Ong, K., Valls, C., Marcos, M.V., Dunger, D.B. & de Zegher, F. 2006. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 91, 2888–2891.
49. Ihlemann, N., Rask-Madsen, C., Perner, A., Dominguez, H., Hermann, T., Køber, L. & Torp-Pedersen, C. 2003. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 285, H875–H882.
50. Ito, T., Yagi, S. & Yamakuchi, M. 2010. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 398, 735–740.
51. Jansson, P.A., Gudbjörnsdóttir, H.S., Andersson, O.K. & Lönnroth, P.N. 1996. The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care 19, 160–164.
52. Jiralerspong, S., Palla, S.L., Giordano, S.H., Meric-Bernstam, F., Liedtke, C., Barnett, C.M., Hsu, L., Hung, M.C., Hortobagyi, G.N. & Gonzalez-Angulo, A.M. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27, 3297–3302.
53. Johnson, J.A., Majumdar, S.R., Simpson, S.H. & Toth, E.L. 2002. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25, 2244–2248.
54. Katakam, P.V., Ujhelyi, M.R., Hoenig, M. & Miller, A.W. 2000. Metformin improves vascular function in insulin-resistant rats. Hypertension 35, 108–112.
55. Kato, H., Sekine, Y., Furuya, Y., Miyazawa, Y., Koike, H. & Suzuki, K. 2015. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 461, 115–121.
56. Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H. & Yasue, H. 1999. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34, 146–154.
57. Kim, E.J. & Um, S.J. 2008. SIRT1: roles in ageing and cancer. BMB Rep 41, 751–756.
58. Kinaan, M., Ding, H. & Triggle, C.R. 2015. Metformin: an old drug for the treatment of diabetes but a new drug for the protection of the endothelium. Med Princ Pract 24, 401–415.
59. Lan, F., Cacicedo, J.M., Ruderman, N. & Ido, Y. 2008. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated kinase activation. J Biol Chem 283, 27628–27635.
60. Langman, L.J. & Kapur, B.M. 2006. Toxicology: then and now. Clin Biochem 39, 498–510.
61. Larsen, S., Rabøl, R., Hansen, C.N., Madsbad, S., Helge, J.W. & Dela, F. 2012. Metformin-treated patients with type 2 diabetes have normal mitochondrial complex 1 respiration. Diabetologia 55, 443–449.
62. Lee, J.M., Seo, W.Y., Song, K.H., Chanda, D., Kim, Y.D., Kim, D.K., Lee, M.W., Ryu, D., Kim, Y.H., Noh, J.R., Lee, C.H., Chiang, J.Y., Koo, S.H. & Choi, H.S. 2010. AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J Biol Chem 285, 32182–32191.
63. Lin, L., Nuotio-Antar, A.M., Ma, X., Liu, F., Fiorotto, M.L. & Sun, Y. 2014. Ghrelin receptor regulates appetite and satiety during aging in mice by regulating meal frequency and portion size but not total food intake. J Nutr 144, 1349–1355.
64. Lipska, K.J., Bailey, C.J. & Inzucchi, S.E. 2011. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 34, 1431–1437.
65. Liu, X., Chhipa, R.R., Pooya, S., Wortman, M., Yachyshin, S., Chow, L.M., Kumar, A., Zhou, X., Sun, Y., Quinn, B. et al. 2014a. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A 111, E435–E444.
66. Liu, X., Chhipa, R.R., Nakano, I. & Dasgupta, B. 2014b. The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 13, 596–605.
67. Lord, J.M., Flight, I.H.K. & Norman, R.J. 2003. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327, 951–953.
68. Ludvigsson, J. 2014. The latest pharmacotherapy options for type 1 diabetes. Expert Opin Pharmacother 15, 37–49.
69. Madiraju, A.K., Erion, D.M., Rahimi, Y., Zhang, X.M., Braddock, D.T., Albright, R.A., Prigaro, B.J., Wood, J.L., Bhanot, S., MacDonald, M.J. et al. 2014. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546.
70. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M. & Melchionda, N. 2001. Metformin in non-alcoholic steatohepatitis. Lancet 358, 893–894.
71. Marfella, R., Acampora, R., Verrazzo, G., Ziccardi, P., De Rosa, N., Giunta, R. & Giugliano, D. 1996. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 9, 934–939.
72. Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., Palacios, H.H., Mote, P.L., Scheibye-Knudsen, M., Gomes, A.P., Ward, T.M., Minor, R.K., Blouin, M.J. et al. 2013. Metformin improves healthspan and lifespan in mice. Nat Commun 4, 2192.
73. Mather, K.J., Verma, S. & Anderson, T.J. 2001. Improved endothelial function with metformin in type 2. J Am Coll Cardiol 37, 1344–1350.
74. Mattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T.A., Jung, S.B., DeRicco, J., Kasuno, K. & Irani, K. 2007. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 104, 14855–14860.
75. Memmott, R.M., Mercado, J.R., Maier, C.R., Kawabata, S., Fox, S.D. & Dennis, P.A. 2010. Metformin prevents tobacco carcinogen–induced lung tumorigenesis. Cancer Prev Res (Phila) 3, 1066–1076.
76. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.P., Giardino, I. & Brownlee, M. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790.
77. Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., Valerio, A., Cantoni, O., Clementi, E., Moncada, S. & Carruba, M.O. 2005. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310, 314–317.
78. Ota, H., Akishita, M., Eto, M., Iijima, K., Kaneki, M. & Ouchi, Y. 2007. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 43, 571–579.
79. Ota, H., Eto, M., Kano, M.R., Ogawa, S., Iijima, K., Akishita, M. & Ouchi, Y. 2008. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 28, 1634–1639.
80. Ouchi, N., Shibata, R. & Walsh, K. 2005. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 96, 838–846.
81. Owen, M.R., Doran, E. & Halestrap, A.P. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3), 607–614.
82. Pernicova, I. & Korbonits, M. 2014. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10, 143–156.
83. Potente, M. & Dimmeler, S. 2008. NO targets SIRT1: a novel signaling network in endothelial senescence. Arterioscler Thromb Vasc Biol 28, 1577–1579.
84. Qin, B., Yang, H. & Xiao, B. 2012. Role of microRNAs in endothelial inflammation and senescence. Mol Biol Rep 39, 4509–4518.
85. Rena, G., Peaeson, E.R. & Sakamoto, K. 2013. Molecular mechanism of action of metformin: old or new insights? Diabetologia 56, 1898–1906.
86. Rocha, G.Z., Dias, M.M., Ropelle, E.R., Osório-Costa, F., Rossato, F.A., Vercesi, A.E., Saad, M.J. & Carvalheira, J.B. 2011. Metformin amplifies chemotherapy-induced AMPK-activation and antitumoral growth. Clin Cancer Res 17, 3993–4005.
87. Rojas, L.B. & Gomes, M.B. 2013. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 15, 6.
88. Ruderman, N.B., Xu, X.J., Nelson, L., Cacicedo, J.M., Saha, A.K., Lan, F. & Ido, Y. 2010. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298, E751–E760.
89. Sakamoto, K., Zarrinpashneh, E., Budas, G.R., Pouleur, A.C., Dutta, A., Prescott, A.R., Vanoverschelde, J.L., Ashworth, A., Jovanović, A., Alessi, D.R. & Bertrand, L. 2006. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 290, E780–E788.
90. Salpeter, S., Greyber, E., Pasternak, G. & Salpeter, E. 2003. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2, CD002967.
91. Sambol, N.C., Chiang, J., O'Conner, M., Liu, C.Y., Lin, E.T., Goodman, A.M., Benet, L.Z. & Karam, J.H. 1996. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36, 1012–1021.
92. Schäfer, G. 1980. Guanidines and biguanides. Pharmacol Ther 8, 275–295.
93. Scheen, A.J. 1996. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30, 359–371.
94. Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., Montminy, M. & Cantley, L.C. 2005. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642–1646.
95. Shu, Y., Brown, C., Castro, R.A., Shi, R.J., Lin, E.T., Owen, R.P., Sheardown, S.A., Yue, L., Burchard, E.G., Brett, C.M. & Giacomini, K.M. 2008. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83, 273–280.
96. Sirtoli, C.R. 1978. Dispositin of metformin (NN-dimethylbiguanide) in man. Clin Pharmacol Ther 24, 683–693.
97. Stein, S., Schafer, N., Breitenstein, A., Besler, C., Winnik, S., Lohmann, C., Heinrich, K., Brokopp, C.E., Handschin, C., Landmesser, U., Tanner, F.C., Lüscher, T.F. & Matter, C.M. 2010. SIRT1 reduces endothelial activation without affecting vascular function in ApoE−/− mice. Aging (Albany, NY) 2, 353–360.
98. Sterne, J. 1957. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.). Maroc Med 36, 1295–1296.
99. Suarez, Y. & Sessa, W.C. 2009. MicroRNAs as novel regulators of angiogenesis. Circ Res 104, 442–454.
100. Suissa, S. & Azoulay, L. 2012. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35, 2665–2673.
101. Tabuchi, T., Satoh, M., Itoh, T. & Nakamura, M. 2012. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 123, 161–171.
102. Tan, B.X., Yao, W.X., Ge, J., Peng, X.C., Du, X.B., Zhang, R., Yao, B., Xie, K., Li, L.H., Dong, H., Gao, F., Zhao, F., Hou, J.M., Su, J.M. & Liu, J.Y. 2011. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 117, 5103–5111.
103. Towler, M.C. & Hardie, D.G. 2007. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100, 328–341.
104. Triggle, C.R. & Ding, H. 2010. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens 4, 102–115.
105. Triggle, C.R. & Ding, H. 2014. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis 5, 245–268.
106. Triggle, C.R., Arunachalam, G., Upadhyay, R., Ding, H. & Triggle, C.R. 2014. Metformin: Targets SIRT1 and microRNAs in microvascular endothelial cells. J Vasc Res 51(Suppl 1), 37 (abstract).
107. Tucker, G.T., Casey, C., Phillips, P.J., Connor, H., Ward, J.D. & Woods, H.F. 1981. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12, 235–246.
108. UK Prospective Diabetes Study Group 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br Med J 317, 703–713.
109. Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M. & Andreelli, F. 2012. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122, 253–270.
110. Vitale, C., Mercuro, G., Cornoldi, A., Fini, M., Volterrani, M. & Rosano, G.M. 2005. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 258, 250–256.
111. Wang, D.S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H. & Sugiyama, Y. 2003. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302, 510–515.
112. Werner, E. & Bell, J. 1921. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 121, 1790–1795.
113. WHO. 2015. Essential medicines. http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_JUN2015.pdf?ua=1.
114. Wilcock, C. & Bailey, C.J. 1994. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24, 49–57.
115. Wilcock, C., Wyre, N.D. & Bailey, C.J. 1991. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol 43, 442–444.
116. Wu, Y., Zhang, C., Dong, Y., Wang, S., Song, P., Viollet, B. & Zou, M.H. 2012. Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo. PLoS One 7, e35508.
117. Xu, Y., Osborne, B.W. & Stanton, R.C. 2005. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol 289, F1040–F1047.
118. Yamakuchi, M., Ferlito, M. & Lowenstein, C.J. 2008. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 105, 13421–13426.
119. Yue, L., Burchard, E.G., Brett, C.M. & Giacomini, K.M. 2008. Effect of genetic variation in the organic cation transporter. Clin Pharmacol Ther 83, 273–280.
120. Yun, H., Lee, M., Kim, S.S. & Ha, J. 2005. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 280, 9963–9972.
121. Zampetaki, A. & Mayr, M. 2012. MicroRNAs in vascular and metabolic disease. Circ Res 110, 508–522.
122. Zhang, Z., Apse, K., Pang, J. & Stanton, R.C. 2000. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 275, 40042–400047.
123. Zhang, T.X., Xu, J.X., Peng, F., Chai, D.J. & Lin, J.X. 2013. Metformin reduces vascular endothelial dysfunction caused by an acute glucose load in patients with hypertension. Blood Press 22, 106–113.
124. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J. & Moller, D.E. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167–1174.
125. Zhu, H. & Leung, S.W. 2015. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 58, 900–911.
126. Zu, Y., Liu, L., Lee, M.Y., Xu, C., Liang, Y., Man, R.Y., Vanhoutte, P.M. & Wang, Y. 2010. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 106, 1384–1393.